|
Volumn 10, Issue 3, 2010, Pages 445-446
|
Editorial: Antibody-based immunosuppression following liver transplantation: The plot thickens
|
Author keywords
[No Author keywords available]
|
Indexed keywords
ALEMTUZUMAB;
BASILIXIMAB;
CALCINEURIN INHIBITOR;
DACLIZUMAB;
INTERLEUKIN 2 RECEPTOR ANTIBODY;
OKT 3;
THYMOCYTE ANTIBODY;
ANTIBODY;
IMMUNOSUPPRESSIVE AGENT;
CHRONIC GRAFT REJECTION;
EDITORIAL;
HEPATITIS C;
HUMAN;
IMMUNOSUPPRESSIVE TREATMENT;
LIVER TRANSPLANTATION;
PRIORITY JOURNAL;
CHEMISTRY;
CLINICAL TRIAL;
GRAFT SURVIVAL;
METABOLISM;
METHODOLOGY;
MULTIVARIATE ANALYSIS;
NOTE;
PREVALENCE;
T LYMPHOCYTE;
TREATMENT OUTCOME;
ANTIBODIES;
CLINICAL TRIALS AS TOPIC;
GRAFT SURVIVAL;
HUMANS;
IMMUNOSUPPRESSION;
IMMUNOSUPPRESSIVE AGENTS;
LIVER TRANSPLANTATION;
MULTIVARIATE ANALYSIS;
PREVALENCE;
T-LYMPHOCYTES;
TREATMENT OUTCOME;
|
EID: 76949105224
PISSN: 16006135
EISSN: 16006143
Source Type: Journal
DOI: 10.1111/j.1600-6143.2009.02972.x Document Type: Editorial |
Times cited : (2)
|
References (5)
|